Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
144.83
+13.16 (9.99%)
At close: Apr 28, 2026, 4:00 PM EDT
145.18
+0.35 (0.24%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 140.84, with a low estimate of 71 and a high estimate of 215. The average target predicts a decrease of -2.75% from the current stock price of 144.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 8 | 9 | 8 |
| Buy | 9 | 9 | 9 | 9 | 9 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 17 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $147 → $171 | Buy | Maintains | $147 → $171 | +18.07% | Apr 22, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $169 | Strong Buy | Reiterates | $169 | +16.69% | Apr 22, 2026 |
| Stifel | Stifel | Strong Buy Reiterates $170 → $215 | Strong Buy | Reiterates | $170 → $215 | +48.45% | Apr 20, 2026 |
| Needham | Needham | Strong Buy Maintains $145 → $186 | Strong Buy | Maintains | $145 → $186 | +28.43% | Apr 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $144 → $167 | Buy | Maintains | $144 → $167 | +15.31% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
54.87M
Revenue Next Year
347.33M
from 54.87M
Increased by 533.02%
EPS This Year
-7.88
from -5.95
EPS Next Year
-6.83
from -7.88
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 262.5M | 939.7M | ||||||
| Avg | 54.9M | 347.3M | ||||||
| Low | n/a | 130.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,612.5% | ||||||
| Avg | - | 533.0% | ||||||
| Low | - | 137.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.14 | -3.37 | ||||||
| Avg | -7.88 | -6.83 | ||||||
| Low | -8.21 | -8.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.